News | Radiopharmaceuticals and Tracers | September 03, 2015

Navidea Awarded $1.8M Grant for Manocept Agent Evaluation in Kaposi’s Sarcoma

Grant will cover preclinical safety trial and clinical trial evaluating detection of KS lesions with SPECT imaging

Navidea, SBIR grant, NCI, NIH, Kaposi's sarcoma, Tc99m tilmanocept, SPECT

Image courtesy of Navidea Biopharmaceuticals Inc.

September 3, 2015 — Navidea Biopharmaceuticals Inc. received initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH). The grant will be used to fund preclinical studies examining the safety of intravenous (IV) injection of Tc99m tilmanocept, a Manocept platform product. This will be followed by a clinical study of the safety and efficacy of single photon emission computed tomography (SPECT) imaging studies to identify and quantify both skin- and organ-associated Kaposi’s Sarcoma (KS) lesions in human patients. 

The SBIR grant is awarded in two parts, with the potential for total grant money of up to $1.8 million over two-and-a-half years. The first six-month funding segment of $300,000, which has already been awarded, is expected to enable Navidea to secure necessary collaborations and Institutional Review Board (IRB) approvals. The second funding segment could provide for up to an additional $1.5 million to accrue participants, perform the Phase 1/2 study, and perform data analyses to confirm the safety and effectiveness of intravenously administered Tc99m tilmanocept.

“Building on earlier research showing KS tumor cells abundantly express CD206, the tilmanocept receptor, and successful imaging with subcutaneous injection, we plan to evaluate intravenous administration of this targeted imaging agent to noninvasively locate internal KS lesions, which are currently challenging to identify and monitor,” commented Toby Maurer, M.D., FAAD, professor of dermatology at the University of California, San Francisco (UCSF), and chief of dermatology at San Francisco General Hospital and Trauma Center, who is co-PI at UCSF with Michael S. McGrath, M.D., PhD. “If successful, future diagnostic and eventually therapeutic developments have the potential to dramatically improve life expectancies and quality of life for patients suffering from Kaposi’s sarcoma.”

For more information: www.navidea.com

Related Content

Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init